Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...
November 4, 2023, 5:37 pm
Apellis pharmaceuticals reports third quarter 2023 financial results
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for...
November 1, 2023, 11:05 am
Apellis announces preliminary u.s. net revenues of approximately $74 million for syfovre® (pegcetacoplan injection) in the third quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting i...
October 5, 2023, 11:00 am
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safet...
July 30, 2023, 5:00 pm
Apellis provides update on review of rare safety events with syfovre® (pegcetacoplan injection) for geographic atrophy
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive...
July 29, 2023, 6:52 pm
Apellis (apls) plunges on safety issues with eye treatment
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan inje...
July 19, 2023, 12:52 pm
Apellis' (apls) study on pegcetacoplan to treat als fails
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral scler...
May 26, 2023, 12:05 pm
Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy
Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the loss of retinal pigmented epithelial and photorece...
April 23, 2023, 10:05 pm
Apellis (apls) stock up 50% in three months: here's why?
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake ...
April 11, 2023, 12:16 pm
Fda approves syfovre™ (pegcetacoplan injection) as the first and only treatment for geographic atrophy (ga), a leading cause of blindness
SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-de...
February 17, 2023, 9:06 pm
Apellis: empaveli ought to win approval for eye disease in february - the future looks bright
Apellis has successfully guided its C3 complement inhibitor pegcetacoplan to an approval in paroxysmal ...
January 27, 2023, 12:29 pm
Apellis (apls) files maa for pegcetacoplan in ga in europe
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atro...
December 19, 2022, 3:02 pm
Apellis shares gain 16% after fda accepts new data for drug submission
Shares of Apellis Pharmaceuticals Inc. APLS, -1.21% jumped 16.8% in premarket trading on Friday after the company said the Food and Drug Administratio...
November 18, 2022, 8:50 am
Apellis to present new long-term data reinforcing the robust efficacy and safety profile of empaveli® (pegcetacoplan) in pnh patients at 2022 ash annual meeting
Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH) Robust impr...
November 3, 2022, 9:05 am
Hc wainwright initiates coverage on upcoming complement franchise company apellis pharmaceuticals
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ: APLS) with a Buy rating and a $75 price target. The analyst expects ...
July 19, 2022, 1:15 pm
Apellis' pegcetacoplan showed continuous, meaningful effects at month 18 in geographic atrophy studies
Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal...
March 16, 2022, 11:59 am
Here's why apellis pharmaceuticals shares are rising
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced...
March 16, 2022, 10:07 am
Apellis shares jump 6% after the company announces new new data for its geographic atrophy drug
Shares of Apellis Pharmaceuticals Inc. APLS, +1.55% gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data d...
March 16, 2022, 8:10 am